Combiflam: Banned In Australia, Here's Why

Combiflam, a popular painkiller medication, has been the subject of controversy in recent years due to concerns over its safety and efficacy. While some sources claim that Combiflam is banned, others refute this, stating that it is only certain batches of the drug that have been recalled or withdrawn. In 2016, the Indian drug regulator, the Central Drugs and Standards Control Authority (CDSCO), found certain batches of Combiflam to be substandard as they failed disintegration tests, leading to a recall by the manufacturer Sanofi. However, there is no indication of a complete ban on the drug in India, and it continues to be one of Sanofi's biggest brands in the country. As for Australia, there is no clear indication of whether Combiflam is banned or not, but the country has been known to ban other medications that remain available in India, such as Analgin.

Explore related products

Advil Dual Action Coated Caplets with Acetaminophen, 125mg Ibuprofen and 250mg Acetaminophen Per Caplet for 8 Hour Pain Relief - 18 Count

$4.28

Motrin Dual Action with Tylenol, Fast-Acting Dual Action Pain Reliever with Ibuprofen & Acetaminophen for Minor Aches & Pains, Ibuprofen (NSAID) 125 mg & Acetaminophen 250 mg, 80 ct

$13.97

Advil Pain Reliever and Fever Reducer, Ibuprofen 200mg for Pain Relief - 24 Coated Tablets

$4.97 $5.49

Advil Dual Action Coated Caplets with Acetaminophen, 250 Mg Ibuprofen and 500 Mg Acetaminophen Per Dose (2 Dose Equivalent) for 8 Hour Pain Relief - 2 Count x 50

$27.88

Flamasil™- for Healthy Inflammation Response* | Multi-Herbal Pain Reliever* and Joint Aid | Bio-Enhanced Turmeric, Boswellia, Resveratrol, and More | 13-in-1 Superfood Antioxidants | 30-Day Supply

$39.95 $42.95

Combiflam is not banned in Australia, but it was recalled in India in 2016

Combiflam, a non-steroidal anti-inflammatory drug, is not banned in Australia. However, in 2016, some batches of the drug were recalled in India.

In May 2016, the French pharmaceutical company Sanofi announced the recall of specific batches of Combiflam. The Indian drug regulator, the Central Drugs and Standards Control Authority (CDSCO), had found these batches to be substandard, as they failed disintegration tests. The affected batches were manufactured in June and July 2015 and had expiry dates of May and June 2018.

Disintegration tests assess the time it takes for tablets and capsules to break down inside the body, a critical factor in the drug's effectiveness. While Combiflam failed this test, Sanofi assured that the delayed disintegration time did not impact the product's safety or efficacy.

Despite the recall, Combiflam was one of the few fixed-drug combinations to survive a crackdown by the Union Health Ministry, which banned 350 combination medicines due to concerns about their medical rationale and side effects.

While Combiflam is not banned in Australia, it is important to note that the availability and regulations of medications can vary by country. It is always advisable to consult a healthcare professional or local authorities for up-to-date information on specific drugs and their legality.

Combiflam is a non-steroidal, anti-inflammatory drug that combines paracetamol and ibuprofen

Paracetamol is a single-ingredient medication used primarily for pain and fever. When combined with ibuprofen in Combiflam, it provides additional anti-inflammatory benefits. Ibuprofen is an NSAID (non-steroidal anti-inflammatory drug) that works by suppressing hormones that cause pain and inflammation in the body. NSAIDs, including ibuprofen, can irritate the stomach lining, so Combiflam is best taken with food to minimise side effects.

Combiflam is effective for treating a range of conditions, including headaches, toothaches, menstrual pain, joint pain, and muscle pain. It can also be used to treat cold and flu symptoms, as it helps to lower high body temperature during a fever. In children, Combiflam can be given but only under the guidance of a healthcare provider, who will determine the appropriate formulation, dosage, and frequency based on the child's age and weight.

While Combiflam is a useful medication, it is not without risks, especially with long-term use. Potential side effects include gastrointestinal issues, kidney problems, allergic reactions, and increased toxicity when interacting with certain other medications. It is important to consult a doctor before taking Combiflam to ensure it is safe for your individual circumstances and to follow the prescribed dosage to avoid adverse effects.

Combiflam was recalled due to failing disintegration tests, which check how long it takes for tablets to break down in the body

Combiflam is a non-steroidal, anti-inflammatory drug that combines paracetamol and ibuprofen. It is one of the most common medicines in India, where it is manufactured by French drugmaker Sanofi. In 2016, Sanofi recalled certain batches of Combiflam after India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), found them to be substandard. Specifically, these batches failed disintegration tests, which check how long it takes for tablets to break down into granules of a minimum specified size inside the body.

The recalled batches of Combiflam were manufactured in June and July 2015 and had expiry dates of May and June 2018. The CDSCO posted notices on its website in February and April 2016, stating that the batches were "not of standard quality". However, Sanofi assured doctors and patients that the delayed disintegration time did not affect the safety or efficacy of Combiflam.

The recall of Combiflam was part of a larger crackdown on low-quality medicines in India. The Drug Controller General of India (DCGI) had highlighted over 100 medicines with quality concerns in the preceding five months, including several popular painkillers. This incident also brought attention to the challenges India faces in effectively banning drugs. While the country's drug regulator can decide which medicines are suitable for its population, there is sometimes pressure to reconsider bans due to the lack of affordable alternatives.

It is important to note that the Combiflam recall in India did not result in a complete ban on the drug. While some sources mention bans on specific medications in Australia, there is no indication that Combiflam is among them. As of 2016, Combiflam was still one of Sanofi's five biggest brands in India, and it continues to be prescribed by pharmacists.

Combiflam was one of the only fixed-drug combinations to survive a purge by the Union health ministry

Combiflam is a non-steroidal, anti-inflammatory drug that is a combination of ibuprofen and paracetamol. It is used to treat pain, inflammation, and fever. In 2016, the Union Health Ministry of India banned 344-350 fixed-drug combinations (FDCs) by issuing a gazette notification. These were banned for a range of reasons, including the lack of medical rationale for marketing such combinations and their untoward side effects.

Despite this, Combiflam was one of the only fixed-drug combinations to survive this purge. There is no bar on the sale of Combiflam, and it is available on prescription. The company has stated that the slower rate of disintegration does not affect the safety or efficacy of the product.

It is important to note that Combiflam has been associated with some side effects. Long-term use may lead to stomach bleeding and kidney problems. It is unsafe to consume alcohol with Combiflam as it may cause excessive drowsiness and increase the risk of liver damage. In addition, Combiflam may be unsafe during pregnancy and breastfeeding, and it can cause decreased alertness and dizziness.

While Combiflam survived the ban on FDCs by the Union Health Ministry, some batches of the drug were recalled in 2016 due to failing drug tests. French drugmaker Sanofi withdrew certain batches of Combiflam manufactured in June-July 2015 and set to expire in May-June 2018. These batches failed to meet the disintegration criteria, which refers to the time it takes for a drug to break down into granules once inside the body. However, this issue was specific to certain batches, and overall, Combiflam remains available and prescribed in India.

Some pharmacists in India still claim Combiflam is available on prescription

Combiflam is a common medicine used to relieve pain, reduce fever, and alleviate inflammation. It is a combination of ibuprofen and paracetamol/acetaminophen, which work together to provide comprehensive relief from various discomforts. While Combiflam was previously available over the counter, there have been reports of it being banned in certain countries. However, some pharmacists in India still claim that Combiflam is available on prescription.

In 2016, the French drugmaker Sanofi withdrew certain batches of Combiflam from the market after they failed to meet the required disintegration criteria. The drug safety alerts posted on the website of India's Central Drugs and Standards Control Authority (CDSCO) stated that the affected batches were manufactured in June-July 2015 and set to expire in May-June 2018. Despite this setback, Combiflam survived a recent purge by the Union Health Ministry, which banned over 350 fixed-dose combination medicines due to concerns about their medical rationale and side effects.

Following the drug recall, there were rumours circulating on WhatsApp and social media platforms that Combiflam had been banned entirely. However, some pharmacists in India continue to assert that Combiflam is still available with a valid prescription. Verification of a drug license and prescription is strongly advised for users before purchasing Combiflam or any other medication. It is important to exercise caution and not blindly trust information circulated on WhatsApp or social media without verification.

While Combiflam may still be prescribed by doctors in India, it is essential to follow the recommended dosage to prevent potential side effects. The typical adult dosage is one tablet taken orally every 6 to 8 hours as needed, not exceeding the maximum daily limit. Additionally, Combiflam should be taken with food or milk to minimise stomach upset, and users should avoid consuming grapefruit or grapefruit juice while taking the medication as it may increase the risk of side effects.

In conclusion, despite the rumours and the recall of certain batches, Combiflam has not been completely banned in India. It remains available with a valid prescription, and pharmacists continue to assure the public of its safety and efficacy when used appropriately under medical supervision. However, it is always advisable to consult a healthcare professional before taking any medication to ensure safe and effective use.

Frequently asked questions